How AI and CPV Can Help in Pharmaceutical Manufacturing
By
Life Sciences Review | Tuesday, October 27, 2020
The pharmaceutical manufacturing companies are using AI and CPV to increase manufacturing drugs' speed and launch it in the market.
FREMONT, CA: The process of pharmaceutical development of novel drugs can be complicated and tedious. The information shared among the multidisciplinary team is essential for decreasing expenses and accelerating the path of bringing the drug to market. To accomplish transparency and actionability of data, the pharmaceutical organizations are developing their manufacturing procedure by digitalizing the data from every equipment.
Technologies like the internet of things (IoT) and clod permit process experts and data scientists to work collaboratively to increase the process understanding and design analytical tools for maintaining the processes under a defined state of control. When this process is followed continuously, it is defined as continuous process verification (CPV). Today, it has become an essential process for the pharmaceutical organization to meet consumers' demands, especially during a global pandemic.
Most importantly, this era's diseases have changed because of the increase in the human population, higher expectancy of life, and the new pandemic viruses are successfully collapsing the healthcare system.
Pharmaceutical organizations have to develop several strategies to produce a wide variety of innovative therapy medicinal products (ATMP) and biological products. The works consist of recombinant proteins, CAR-T cells and oncolytic viruses, monoclonal antibodies, and recombinant proteins to deliver new medical requirements in the society.
The pharmaceutical companies have to deal with the constant social pressure of delivering drug products to the market to treat a disease that does not have any current treatment. Due to COVID-19, pharmaceutical organizations have advanced rapidly through every clinical development stage in the last few months, and many companies have already reached phase three of the clinical trial. The regulatory authorities have marked the guidelines for preventing non-effective vaccines and ensuring the safety requirement for delivering an efficient product. In such a situation, the pharma teams' process development must be decreased so that they provide a practical manufacturing process for reaching the GMP clinical manufacturing in less time.
See also: Top IoT Companies
